JP2018506511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506511A5 JP2018506511A5 JP2017531626A JP2017531626A JP2018506511A5 JP 2018506511 A5 JP2018506511 A5 JP 2018506511A5 JP 2017531626 A JP2017531626 A JP 2017531626A JP 2017531626 A JP2017531626 A JP 2017531626A JP 2018506511 A5 JP2018506511 A5 JP 2018506511A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- group
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims description 9
- 239000005557 antagonist Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 6
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010059282 Metastases to central nervous system Diseases 0.000 claims description 4
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 150000003456 sulfonamides Chemical class 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462091200P | 2014-12-12 | 2014-12-12 | |
| US62/091,200 | 2014-12-12 | ||
| PCT/IB2015/059525 WO2016092508A1 (en) | 2014-12-12 | 2015-12-10 | Treatment of breast cancer brain metastases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506511A JP2018506511A (ja) | 2018-03-08 |
| JP2018506511A5 true JP2018506511A5 (enExample) | 2019-01-24 |
| JP6847835B2 JP6847835B2 (ja) | 2021-03-24 |
Family
ID=55024190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531626A Expired - Fee Related JP6847835B2 (ja) | 2014-12-12 | 2015-12-10 | 乳がん脳転移の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10689459B2 (enExample) |
| EP (1) | EP3229803B1 (enExample) |
| JP (1) | JP6847835B2 (enExample) |
| CN (1) | CN108367003B (enExample) |
| ES (1) | ES2784900T3 (enExample) |
| WO (1) | WO2016092508A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110115758B (zh) * | 2018-02-05 | 2021-05-11 | 中山大学 | Pik3ip1蛋白在调节t细胞反应和制备抗肿瘤药物中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| WO1998031346A1 (en) | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| TWI471134B (zh) | 2007-09-12 | 2015-02-01 | Genentech Inc | 肌醇磷脂３－激酶抑制劑化合物及化療劑之組合及使用方法 |
| CA2701292C (en) | 2007-10-25 | 2015-03-24 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| KR20100131446A (ko) | 2008-03-05 | 2010-12-15 | 노파르티스 아게 | Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도 |
| PL2606070T3 (pl) * | 2010-08-20 | 2017-06-30 | Novartis Ag | Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3) |
| AU2012349735B2 (en) | 2011-12-05 | 2016-05-19 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| HK1211476A1 (en) | 2012-08-16 | 2016-05-27 | Novartis Ag | Combination of pi3k inhibitor and c-met inhibitor |
| WO2014177915A1 (en) * | 2013-05-01 | 2014-11-06 | Piramal Enterprises Limited | Cancer combination therapy using imidazo[4,5-c]quinoline derivatives |
| ES2729202T3 (es) | 2014-07-16 | 2019-10-30 | Dana Farber Cancer Inst Inc Et Al | Inhibición de HER3 en cánceres ováricos serosos de grado bajo |
-
2015
- 2015-12-10 CN CN201580075191.0A patent/CN108367003B/zh not_active Expired - Fee Related
- 2015-12-10 WO PCT/IB2015/059525 patent/WO2016092508A1/en not_active Ceased
- 2015-12-10 US US15/535,405 patent/US10689459B2/en not_active Expired - Fee Related
- 2015-12-10 JP JP2017531626A patent/JP6847835B2/ja not_active Expired - Fee Related
- 2015-12-10 EP EP15816534.0A patent/EP3229803B1/en active Active
- 2015-12-10 ES ES15816534T patent/ES2784900T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7507209B6 (ja) | がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ | |
| KR102349056B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| Awada et al. | Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy | |
| CN110536905B (zh) | 用于治疗肺癌的抗pd-1抗体 | |
| JP6774421B2 (ja) | がんの治療のための方法、組成物、及びキット | |
| Wei et al. | Safety and efficacy of venetoclax plus low-dose cytarabine in treatment-naive patients aged≥ 65 years with acute myeloid leukemia | |
| JP2016502504A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2015534580A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2024513505A (ja) | 腫瘍を治療するための組成物及び方法 | |
| JP2020506945A (ja) | がんの治療のための方法、組成物及びキット | |
| AU2012253858B2 (en) | Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-ErbB3 agents | |
| JP2019048822A (ja) | Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用 | |
| AU2017206108A1 (en) | Combination of a chromene compound and a second active agent | |
| JP2019524714A5 (enExample) | ||
| US20220195059A1 (en) | Rank Pathway Inhibitors in Combination with CDK Inhibitors | |
| WO2020123477A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
| JP2018506511A5 (enExample) | ||
| JP2024529451A (ja) | がんを治療するための方法及び組成物 | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| WO2023174210A1 (en) | Combination treatment for cancer | |
| EP2968539A1 (en) | Combination/adjuvant therapy for wt-1-positive disease | |
| Torka et al. | Ofatumumab plus Hypercvad/MA induction leads to high rates of minimal residual disease (MRD) negativity in patients with newly diagnosed mantle cell lymphoma, results of a phase 2 study |